Ionis Pharmaceuticals

We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy. 

Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
Company Growth (employees)
Type
Public
HQ
Carlsbad, US
Founded
1989
Size (employees)
435 (est)+2%
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, US

Key People at Ionis Pharmaceuticals

Stanley Crooke

Stanley Crooke

CEO
Lynne Parshall

Lynne Parshall

COO / CFO
Elizabeth L. Hougen

Elizabeth L. Hougen

Chief Accounting Officer
C. Frank Bennett

C. Frank Bennett

Senior Vice President of Research
Sarah Boyce

Sarah Boyce

CBO
Steve Hughes

Steve Hughes

Chief Clinical Development Officer
Brett P. Monia

Brett P. Monia

Senior Vice President of Antisense Drug Discovery

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, US (HQ)
2855 Gazelle Ct

Ionis Pharmaceuticals Data and Metrics

Ionis Pharmaceuticals Financial Metrics

Ionis Pharmaceuticals's revenue was reported to be $346.6 m in FY, 2016 which is a 22% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

346.6 m

Revenue growth (FY, 2015 - FY, 2016), %

22%

Net income (FY, 2016)

(86.6 m)

EBIT (FY, 2016)

(46.3 m)

Market capitalization (25-May-2017)

5.8 b

Closing share price (25-May-2017)

46.6

Cash (31-Dec-2016)

84.7 m
Ionis Pharmaceuticals's current market capitalization is $5.8 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

147.3 m214.2 m283.7 m346.6 m

Revenue growth, %

45%32%22%

Operating expense total

199 m261.9 m359.5 m392.9 m

EBIT

(51.7 m)(47.7 m)(75.8 m)(46.3 m)

EBIT margin, %

(35%)(22%)(27%)(13%)

Interest expense

19.4 m22.2 m36.7 m38.8 m

Income tax expense

5.9 m15.4 m(372 k)(2.9 m)

Net Income

(60.6 m)(39 m)(88.3 m)(86.6 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

160 m143 m128.8 m84.7 m

Accounts Receivable

Inventories

8 m6.3 m6.9 m7.5 m

Current Assets

735.5 m836.6 m837 m797.9 m

PP&E

86.2 m89 m90.2 m92.8 m

Total Assets

847.2 m955.8 m956.1 m912.5 m

Accounts Payable

11 m18 m28.4 m21.1 m

Current Liabilities

97.8 m115.3 m148.9 m133.8 m

Additional Paid-in Capital

1.3 b1.2 b1.3 b1.3 b

Retained Earnings

(967.6 m)(1 b)(1.1 b)(1.2 b)

Total Equity

378.4 m257.8 m200.8 m99.6 m

Financial Leverage

2.2 x3.7 x4.8 x9.2 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(60.6 m)(39 m)(88.3 m)(86.6 m)

Depreciation and Amortization

6.6 m6.4 m7 m7.5 m

Accounts Receivable

Inventories

(1.9 m)1.7 m(609 k)(590 k)

Accounts Payable

66 k4.8 m9.2 m(10.7 m)

Cash From Operating Activities

63.5 m6.3 m21.1 m(112.1 m)

Purchases of PP&E

(1.6 m)(7.5 m)(7.7 m)(7.1 m)

Cash From Investing Activities

(255.7 m)(82.8 m)(60.1 m)56.6 m

Cash From Financing Activities

227.7 m59.6 m24.7 m11.4 m

Interest Paid

6 m6.4 m6.8 m7.3 m

Income Taxes Paid

(4 m)1.1 m
Y, 2016

Financial Leverage

9.2 x

Ionis Pharmaceuticals Market Value History

Ionis Pharmaceuticals Job Categories

Ionis Pharmaceuticals Online and Social Media Presence

Ionis Pharmaceuticals News and Updates

Ionis Pharmaceuticals Company Life and Culture

You may also be interested in